SHA:601607 Revenue

Shanghai Pharmaceuticals Holding had revenue of 73.48B CNY in the quarter ending September 30, 2025, with 4.65% growth. This brings the company's revenue in the last twelve months to 280.69B, up 3.04% year-over-year. In the year 2024, Shanghai Pharmaceuticals Holding had annual revenue of 275.25B with 5.75% growth.

Revenue (ttm)

280.69B

Revenue Growth

+3.04%

P/S Ratio

0.21

Revenue / Employee

5.68M

Employees

49,402

Market Cap

60.08B

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	275.25B	14.96B	5.75%
Dec 31, 2023	260.30B	28.31B	12.21%
Dec 31, 2022	231.98B	16.16B	7.49%
Dec 31, 2021	215.82B	23.92B	12.46%
Dec 31, 2020	191.91B	5.34B	2.86%
Dec 31, 2019	Pro	Pro	Pro
Dec 31, 2018	Pro	Pro	Pro
Dec 31, 2017	Pro	Pro	Pro
Dec 31, 2016	Pro	Pro	Pro
Dec 31, 2015	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Jiangsu Hengrui Pharmaceuticals Co.,Ltd	30.98B
WuXi AppTec	43.88B
Shenzhen Mindray Bio-Medical Electronics	33.07B
Sichuan Biokin Pharmaceutical	2.23B
Shanghai United Imaging Healthcare	12.20B
Aier Eye Hospital Group	22.17B
Zhangzhou Pientzehuang Pharmaceutical.,	9.78B
Yunnan Baiyao Group Co.,Ltd	40.77B

Revenue Rankings

Shanghai Pharmaceuticals Holding News

1 year ago - Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million - Benzinga
1 year ago - HUTCHMED to divest 45% stake in JV with Shanghai Pharma - Seeking Alpha

More News